Our News

Published Scientific Articles

NP-ALT, a Liposomal:Peptide Drug, Blocks p27Kip1 Phosphorylation to Induce Oxidative Stress, Necroptosis, and Regression in Therapy-Resistant Breast Cancer Cells

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture

Concarlo in the News

Life Sciences Review special edition on BioTech Startup 2022

US biotech start-up set to have huge impact on breast cancer treatment landscape

Concarlo: targeting proliferation and resistance in one go

Webinars & Talks

Beyond Biotech podcast 24: Concarlo Therapeutics

LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics

Opportunity to Join the Fight Against Metastatic Breast Cancer

Concarlo is on a Mission to Rid the World of Metastatic Breast Cancer


“The reward for work well done is the opportunity to do more”

—Jonas Salk

RESI’s Innovator’s Pitch Challenge Winner

Princeton University Women’s Showcase

The 50 Most admired companies: CIO Bio

Top 100 entreprenuers: Alumni List

Top Biotech Startup 2022
Awarded by: Life Sciences Review